It is Estimated that 200 Million people worldwide
are living with Cardiovascular Disease
It is Estimated that 200 Million people worldwide are living with Cardiovascular Disease

Do you know the Leading Cause of Death?

Do you know the
Leading Cause of Death?

  • Cardiovascular Disease is the world’s single biggest killer; it caused nearly 1MILLION deaths in the US alone in 2020
  • The prevalence for men is 7.0 %; for women it is 4.2 % in the US
  • Over 6 million people in the US have heart failure (HF); over 26 million people worldwide
  • Roughly 50% of HF patients have Diastolic Heart Failure (DHF) more commonly referred to as HFpEF
  • Significant unmet need: most medicines that work in systolic HF (HFrEF or HFmrEF) do not work in diastolic heart failure and do not change mortality

~1 Million NEW cases of Heart Failure
are diagnosed in the US per year
~1 Million NEW cases of Heart Failure
are diagnosed in the US per year

Defining Heart Failure-Systolic & Diastolic

Defining Heart Failure
Systolic & Diastolic

Heart failure happens when the heart cannot pump enough blood and oxygen to support normal function of the other organs in the body

What is Systolic Heart Failure-
SHF is heart failure where there is contractile dysfunction causing the heart pushes reduced oxygenated blood to the tissues, HFrEF

What is Diastolic Heart Failure-
DHF is heart failure in the absence of contractile dysfunction and with evidence of diastolic relaxation dysfunction. DHF patients have Preserved Ejection Fraction, (EF>50%) the fraction of the blood in the left ventricle that is pushed into the aorta and circulation with each beat, often referred to as HFpEF

Building the Next Generation Heart Company
Building the Next Generation Heart Company

Diastol Therapeutics Mission

Diastol Therapeutics Mission

We are an Emerging Biotechnology Company Developing Treatment for Heart Failure with Preserved Ejection Fraction as our lead program.

We will build a Cardiovascular Focused Company to treat leading causes of death and morbidity for all as we age.

See Overview

what we’re doing and where do we go

what we’re doing & where do we go

  • We are actively exploring our capital needs and strategic objectives to lead our pipeline into the clinic with our lead program through Ph 1/2 Clinical Trials
  • Further develop our compliment of diagnostics and biomarkers along with our secondary therapeutic market
  • Explore building a leading Cardiovascular company with in-licensing of compelling assets
  • Build team and physical space for expansive platform development of cutting-edge technology to IMPROVE PATIENT LIVES

If you are interested in helping build a great company focused on improving the lives of each of us, or our mothers, fathers, siblings, children and friends, please reach out

Contact Us
Our Lead Compound, Mito-58
Reduces Reactive Oxygen Species (ROS)
Our Lead Compound, Mito-58
Reduces Reactive Oxygen Species (ROS)

Mito-58 is a compound that specifically TARGETS the MITOCHODRIA (MITO (mito, triphenylphosphonium)) AND a free radical scavenger (TEMPO) linked together

Concentrated in the mitochondria and not targeting to a specific receptor, allows for iterative moieties of the “mito”, “TEMPO” and the “linker” portion which led us to develop our proprietary library of compounds, including Mito-58

Screening for additional compounds with mitochondrial directed activity is being explored for portfolio expansion

Stacks Image 584
MOA: Improvement of Mitochondrial Function
MOA: Improvement of Mitochondrial Function
Leadership understands Cardiovascular Disease
Leadership understands Cardiovascular Disease

We leverage the Best and the Brightest in the Scientific and Life Science Community, and drives toward Success to improve our Heart Health.

Our Management, Executive Advisors and Scientific Key Opinion Leaders have over a century of experience in life sciences, drug development and emerging Biotechnology and MedTech companies. We are dedicated to building a cardiovascular focused company that can develop products that will improve the lives of millions of people across the globe.

We will be stewards of cutting-edge science and open to rewarding collaborations as they arise. Our team is extraordinarily trained, educated and thoughtful across the cardiovascular arena and beyond. Such experiences will lead us to uncover the best path forward for treating Heart Failure, monitoring treatment success, and broadening to treating Atrial Fibrillation. We look forward to sharing our journey with you!

Image

Diastol Therapeutics
4925 Weston Lane N
Plymouth, MN 55446

Phone: 312-238-9017
michaelb@diastol.com

© 2024 Diastol Therapeutics